MediLink Therapeutics focuses on developing competitive drug conjugates internationally. With independent intellectual property rights, MediLink Therapeutics develops the next generation of conjugate technologies. The future products will provide better therapeutic windows for the unmet clinical needs. MediLink Therapeutics strives to upgrade technologies, establish diverse technology platforms for drug conjugates, and expand into new disease areas to serve global patients continuously.
Company Details
- Employees
- 45
- Address
- B3-101, Bio-Industrial Park, 218, Xinghu Street, Suzhou,jiangsu,china
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.medilinkthera.com
- Keywords
- Antibody Drug Conjugates, Oncology, Drug Discovery & Research, Drug Development, Technology Collaboration.
- HQ
- Suzhou, Jiangsu
Medilink Therapeutics Questions
Medilink Therapeutics's website is http://www.medilinkthera.com
Medilink Therapeutics's LinkedIn profile is https://www.linkedin.com/company/mltx
Medilink Therapeutics has
45 employees.
View email and phone details for 45
employees at Medilink Therapeutics.
Medilink Therapeutics's industry is
Biotechnology Research
Medilink Therapeutics's top competitors are
Cardurion Pharmaceuticals,
Formation Bio,
Metsera,
Mirador Therapeutics,
Seaport Therapeutics,
Ascidian Therapeutics,
Iambic Therapeutics,
Lifordi Immunotherapeutics, Inc.,
Xaira Therapeutics,
Capstan Therapeutics.
Medilink Therapeutics's categories are Biotechnology Research
